Cargando…

The Comparability of Anti-SARS-CoV-2 IgG Levels Measured with Different Immunoassays Varies over Time after Primary BNT162b2 Vaccination and Homologous Booster Immunization

Detalles Bibliográficos
Autores principales:	Salvagno, Gian Luca, Lippi, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769787/ https://www.ncbi.nlm.nih.gov/pubmed/36354360 http://dx.doi.org/10.1128/spectrum.03022-22

Ejemplares similares

Correlation between Anti-SARS-CoV-2 Total Antibodies and Spike Trimeric IgG after BNT162b2 Booster Immunization
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Anti-SARS-CoV-2 IgG antibodies in patients with or without SARS-CoV-2 infection after BNT162b2 vaccine booster
por: Salvagno, G.L., et al.
Publicado: (2022)

The strength of association between pre-and post-booster BNT162b2 anti-SARS-CoV-2 antibodies levels depends on the immunoassay
por: Salvagno, Gian Luca, et al.
Publicado: (2021)

Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA
por: Danese, Elisa, et al.
Publicado: (2021)

Impact of BNT162b2 primary vaccination and homologous booster on anti-SARS-CoV-2 IgA antibodies in baseline seronegative healthcare workers
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Comparative longitudinal variation of total IgG and IgA anti-SARS-CoV-2 antibodies in recipients of BNT162b2 vaccination
por: Lippi, Giuseppe, et al.
Publicado: (2021)

Variation of Total Anti-SARS-CoV-2 Antibodies After Primary BNT162b2 Vaccination and Homologous Booster
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers
por: Salvagno, Gian Luca, et al.
Publicado: (2021)

Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders
por: Sauerwein, Kai M.T., et al.
Publicado: (2023)

Serum C reactive protein predicts humoral response after BNT162b2 booster administration
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Variación longitudinal comparativa de los anticuerpos totales, IgG e IgA contra el SARS-CoV-2 en receptores de la vacuna BNT162b2
por: Lippi, Giuseppe, et al.
Publicado: (2022)

Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster
por: Lau, Chin Shern, et al.
Publicado: (2022)

Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination
por: Grupel, Daniel, et al.
Publicado: (2021)

Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees
por: Low, Jia Ming, et al.
Publicado: (2021)

BNT162b2 Third Booster Dose Significantly Increases the Humoral Response Assessed by Both RBD IgG and Neutralizing Antibodies in Renal Transplant Recipients
por: Hod, Tammy, et al.
Publicado: (2022)

Enhanced SARS-CoV-2 IgG durability following COVID-19 mRNA booster vaccination and comparison of BNT162b2 with mRNA-1273
por: Ailsworth, Samuel M., et al.
Publicado: (2023)

The Antibody Response to the BNT162b2 mRNA COVID-19 Booster in Healthcare Workers: Association between the IgG Antibody Titers and Anthropometric and Body Composition Parameters
por: Golec, Marlena, et al.
Publicado: (2022)

Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers
por: Bayart, Jean-Louis, et al.
Publicado: (2021)

Impacto de la vacunación primaria con BNT162b2 y una dosis de refuerzo homóloga en los anticuerpos IgA contra SARS-CoV-2 en profesionales sanitarios seronegativos
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Analytical evaluation of the novel Lumipulse G BRAHMS procalcitonin immunoassay
por: Ruzzenente, Orazio, et al.
Publicado: (2016)

Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers
por: Salvagno, Gian Luca, et al.
Publicado: (2021)

Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naïve BNT162b2 vaccine recipients
por: Azzi, Lorenzo, et al.
Publicado: (2021)

Occurrence of BNT162b2 Vaccine Adverse Reactions Is Associated with Enhanced SARS-CoV-2 IgG Antibody Response
por: Rechavi, Yoav, et al.
Publicado: (2021)

Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines
por: Montoya, José G., et al.
Publicado: (2021)

Immunoassay for quantification of antigen-specific IgG fucosylation
por: Šuštić, Tonći, et al.
Publicado: (2022)

Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine
por: Lo Sasso, Bruna, et al.
Publicado: (2021)

Immunogenicity and Safety of BNT162b2 Homologous Booster Vaccination in People Living with HIV under Effective cART
por: Gianserra, Laura, et al.
Publicado: (2022)

Immune response (IgG) following full inoculation with BNT162b2 COVID-19 mRNA among healthcare professionals
por: Tsatsakis, Aristidis, et al.
Publicado: (2021)

Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy
por: Giossi, Riccardo, et al.
Publicado: (2022)

Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents
por: Jeulin, Helene, et al.
Publicado: (2022)

BNT162b2 Vaccine Booster and Mortality Due to Covid-19
por: Arbel, Ronen, et al.
Publicado: (2021)

Frosted branch angiitis after booster vaccination with BNT162b2
por: Haas, A.-M., et al.
Publicado: (2023)

Clinical Evaluation of Antiphospholipase A2 Receptor IgG4 level and Its IgG4-to-IgG Ratio Based on Quantitative Immunoassays in Idiopathic Membranous Nephropathy
por: Zhang, Yi, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon
por: Moghnieh, Rima, et al.
Publicado: (2021)

Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose
por: Gareayaghi, Nesrin, et al.
Publicado: (2022)

IgG Antibody Response to the Pfizer BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers with Healthy Weight, Overweight, and Obesity
por: Bates, John T., et al.
Publicado: (2022)

Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine
por: Lo Sasso, Bruna, et al.
Publicado: (2022)

Vaccine‐induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster
por: Favresse, Julien, et al.
Publicado: (2022)

Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
por: Choi, Seong-Ho, et al.
Publicado: (2023)

Dynamics of anti-Spike IgG antibody level after the second BNT162b2 COVID-19 vaccination in health care workers
por: Ikezaki, Hiroaki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m4gmvsvfj8dkg2ocig35ql1tq3